Navigation Links
Bioscience to battle ash dieback
Date:3/7/2013

n Forest and Landscape Institute. The research will also complement a project funded by the Natural Environment Research Council (NERC) at Queen Mary University of London to decipher the ash tree's genetic code.

Genome sequences of up to 30 samples of the fungus from the UK and Europe will rapidly help to acquire in-depth genetic information to shed light on the infection process. These data will reveal clues to the origins of the disease and provide genetic 'markers' to allow the spread of different strains of the fungus to be followed. Genetic data will also provide direct insights into the nature of the fungus.

The consortium will obtain information about how the disease spreads by studying infection in climate-controlled growth facilities, tracking the fungus as it colonises the plant. This vital information will help to develop effective disease control strategies.

The project will also uncover how some ash trees can partially resist attack. About 2% of Danish trees appear to ward off the disease but little information on the genetic basis for this is known. Genetic data from these trees will be compared to susceptible trees to find variations in their genetic codes. By identifying these differences, genetic makers can be developed to help breeders produce more resistant trees.

The Nornex consortium, named for the three Norns who tend the ash tree of life 'Yggdrasil' in Norse mythology, will upload its data to an open-access website. This crowd-sourced, data-sharing approach will share the genetic data to exploit the expertise of plant and fungal research communities internationally.

Charting the disease

In addition to the consortium, Professor Christopher Gilligan with Dr Nik Cunniffe at the University of Cambridge and Dr Frank van den Bosch Rothamsted Research, have been awarded funding to develop and test mathematical, computer-based models to
'/>"/>

Contact: Rob Dawson
rob.dawson@bbsrc.ac.uk
01-793-413-204
Biotechnology and Biological Sciences Research Council
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Althea Technologies & Profectus BioSciences Sign Manufacturing Agreement For Plasmid DNA Production
2. Inspiring teens with research virus: Expert-mentored bioscience contest proves a powerful vector
3. Major international push to maximize bioscience research to help worlds poorest farmers
4. Academia should fulfill social contract by supporting bioscience startups, case study says
5. Could bioscience research bring more Olympic and Paralympic medals
6. 3-V Biosciences Appoints Douglas I. Buckley, PhD, as Vice President of Biology
7. PuraMed BioScience®, Inc., Launches a Marketing Blitz for LipiGesic® M, Its Clinically-Tested Migraine Pain Reliever in the Denver, CO Region to Coincide with the NACDSs Marketplace 2012 Trade Convention
8. Amarantus BioSciences to Present at the National Investment Banking Associations (NIBA)122nd Conference in New York City
9. HUNT Biosciences and SomaLogic collaborate to validate protein biomarkers of cardiovascular risk
10. Artificial platelets could treat injured soldiers on the battlefield
11. Gene associated with high anxiety can have protective effect on the battlefield
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... soup in which life arose have been maintained in our ... Anglia. , Research published today in the Journal of ... very likely also in animals still perform ancient reactions thought ... some four billion years ago. , The primordial soup theory ... a result of the combination of metals, gases from the ...
(Date:7/24/2014)... in German . ... asthma sufferers worldwide, a further 600 million people living ... global population contending with allergic rhinitis (allergic inflammation of ... other organs and parts of the body beyond the ... the form of inflammatory bowel diseases such as colitis ...
(Date:7/24/2014)... doctors and scientists from Singapore have developed Asia,s first ... eye disease that affects the cornea called corneal stromal ... vision. , Called the POLARIS TGFBI (Transforming Growth ... to aid in the diagnosis and management of patients ... members carrying a TGFBI mutation who may also be ...
Breaking Biology News(10 mins):New drugs to combat asthma and the like 2New drugs to combat asthma and the like 3Singapore team develops Asia's first genetic test that can prevent corneal blindness 2Singapore team develops Asia's first genetic test that can prevent corneal blindness 3
... leaf has revealed the oldest known evidence of a macabre ... to turn them into zombies. The discovery has been ... Hughes, from the University of Exeter, who studies parasites that ... manner of animals are susceptible to the often deadly body ...
... from Mount Sinai School of Medicine have enhanced our ... conversion, the process in which food is converted into ... scientists gain atomic-level insight into how organisms synthesize their ... published in the August issue of PLoS Biology ...
... Mont. -- Researchers at Montana State University have ... for treating antibiotic resistant infections, fungal infections and viral ... to study such compounds. The technologies are ... The first technology involves an existing clinical drug ...
Cached Biology News:Fossil reveals 48-million-year history of zombie ants 2Mount Sinai researchers discover new mechanism behind cellular energy conversion 2Montana State University offers 6 new biomedical technologies for licensing 2Montana State University offers 6 new biomedical technologies for licensing 3Montana State University offers 6 new biomedical technologies for licensing 4
(Date:7/24/2014)... Texas (PRWEB) July 24, 2014 ... Potassium Sulphate Industry” is a professional and in-depth ... report introduces Potassium Sulphate basic information, including ... and industry overview. This research covers the international ... as global industry analysis covering macroeconomic environment & ...
(Date:7/24/2014)... 24, 2014 The first part of ... in First in Human Studies” will cover comprehensive clinical ... decisions. , With increasing R&D costs and declining industry ... to maximize the knowledge collected in early Phase I/IIa ... success in late stage development. , Next, the presenters ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 As part ... numerous projects in the MENA region during 2014 with ... a preferred provider agreement with DZS to manage our ... region,” said Global VP of R&D and President of ... developed excellent operational practices with a focus on utilizing ...
(Date:7/23/2014)... July 23, 2014  Sangamo BioSciences, Inc. (NASDAQ: ... financial results and accomplishments. For the ... consolidated net loss of $7.0 million, or $0.10 per ... or $0.10 per share, for the same period in ... cash, cash equivalents, marketable securities and interest receivable of ...
Breaking Biology Technology:Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 4Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks 2SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services 2Sangamo BioSciences Reports Second Quarter 2014 Financial Results 2Sangamo BioSciences Reports Second Quarter 2014 Financial Results 3Sangamo BioSciences Reports Second Quarter 2014 Financial Results 4Sangamo BioSciences Reports Second Quarter 2014 Financial Results 5Sangamo BioSciences Reports Second Quarter 2014 Financial Results 6Sangamo BioSciences Reports Second Quarter 2014 Financial Results 7Sangamo BioSciences Reports Second Quarter 2014 Financial Results 8Sangamo BioSciences Reports Second Quarter 2014 Financial Results 9
... enhances Microsoft Amalga Life Sciences to accelerate basic research ... June 1 Microsoft Corp. today announced that it ... to acquire certain assets of Rosetta Biosoftware, a business ... of Merck & Co. Inc. The deal allows Microsoft ...
... Move strengthens Kendle,s position as a global clinical ... , CINCINNATI, June 1 Kendle (Nasdaq: ... research organization, today announced the opening of offices ... Philippines. The new operations provide Kendle,s global ...
... , ADHD symptom control demonstrated from the first time ... , PHILADELPHIA, June 1 Shire ... global specialty biopharmaceutical company, today announced that the US ... to the prescribing information for its once-daily Attention Deficit ...
Cached Biology Technology:Microsoft Signs Agreement With Merck & Co. Inc. to Acquire Assets of Rosetta Biosoftware, Strengthening Position in Life Sciences Industry 2Microsoft Signs Agreement With Merck & Co. Inc. to Acquire Assets of Rosetta Biosoftware, Strengthening Position in Life Sciences Industry 3Kendle Expands Asia/Pacific Operations with Opening of Offices in Kuala Lumpur, Bangkok and Manila 2Kendle Expands Asia/Pacific Operations with Opening of Offices in Kuala Lumpur, Bangkok and Manila 3FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 2FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 3FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 4FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 5FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 6FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 7
delta-like 1 homolog (Drosophila)...
ELISpot kit for human Granzyme B. Kits contain PVDF plates, capture & detection antibodies, streptavidin-ALP, BSA, Skimmed dry milk, BCIP/NTB substrate, and wash buffer...
SHEEP ANTI ECHIS OCCELATUS (VENOM)...
MOUSE ANTI RAT KAPPA/LAMBDA:HRP Immunogen: MARK-1: Rat kappa light chains (IR202 and IR968)MARL-15: Rat lambda light chains (RH58, IR31)...
Biology Products: